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To investigate trends in travel-associated morbidity 
with particular emphasis on emerging infections with 
the potential for introduction into Europe, diagnoses of 
7,408 returning travellers presenting to 16 EuroTravNet 
sites in 2010 were compared with 2008 and 2009. A 
significant increase in reported Plasmodium falcipa-
rum malaria (n=361 (6% of all travel-related morbidity) 
vs. n=254 (4%) and 260 (5%); p<0.001), P. vivax malaria 
(n=51 (1%) vs. n=31 (0.5%) and 38 (1%); p=0.027) and 
dengue fever (n=299 (5%) vs. n=127 (2%) and 127 
(2%); p<0.001) was observed. Giardia lamblia was 
identified in 16% of patients with acute diarrhoea, 
with no significant annual variation. The proportion of 
acute diarrhoea due to Campylobacter increased from 
7% in 2008 to 12% in 2010 (p=0.001). We recorded 121 
patients with pulmonary tuberculosis in 2010, a three-
fold increase in the proportionate morbidity from 2008 
to 2010. In 2010, 60 (0.8%) cases of chronic Chagas 
disease, 151 (2%) cases of schistosomiasis and 112 
(2%) cases of cutaneous larva migrans were reported. 
Illness patterns in sentinel travellers, captured by 
EuroTravnet, continue to highlight the potential role of 
travellers in the emergence of infectious diseases of 
public health concern in Europe and the relevance of 
offering medical travel advice and enforcing specific 
and adequate prophylaxis.
Introduction
EuroTravNet (www.eurotravnet.eu), a network of clini-
cians who are specialists in tropical and travel medi-
cine, was founded in 2008. It includes 16 EuroTravNet 
sites staffed by clinicians that have demonstrated 
training, experience, and/or significant publications in 
travel or tropical medicine. Sites in France, Germany, 
Italy, the Netherlands, Norway, Portugal, Spain, 
Sweden, Switzerland and the United Kingdom, partici-
pate in surveillance and monitoring of travel-related 
illnesses by collecting epidemiological data on return-
ing ill travellers using the GeoSentinel technology 
platform (www.geosentinel.org) [1-3]. Network-based 
surveillance data allow for patient diagnoses, chronol-
ogy of travel, and standardised exposure details to be 
collected for detailed analysis of travel-related mor-
bidity. In addition, such networks can detect disease 
outbreaks through sentinel travellers, enhance surveil-
lance, and facilitate rapid communication, response 
and dissemination of information among healthcare 
providers and public health partners. A good example 
of efficient detection of outbreaks among travellers 
was the recent report of a cluster of travellers return-
ing from Tioman Island, Malaysia with muscular sarco-
cystosis [4].
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This report describes the spectrum of selected infec-
tious diseases in European travellers in 2010, and com-
pares these numbers with the data sets from 2008 and 
2009. Thanks to the multi-centre nature of EuroTravNet, 
which provided a large number of ill travellers from 
many countries with different reasons for travelling, 
we were able to capture statistically significant trends 
in imported infectious diseases over a relatively short 
period of three years.
Methods
The detailed methods for patient recruitment, inclu-
sion criteria, and limitations of the GeoSentinel data-
base have been described elsewhere [1-3,5]. In brief, 
patients must have crossed an international border, 
including borders within Europe, before the clinic visit 
and must have sought medical advice for a presumed 
travel-related illness or for screening for asymptomatic 
infection. All ill patients presenting to EuroTravNet 
sites are systematically and prospectively included in 
the GeoSentinel database provided the diagnosis is 
clinically or laboratory-confirmed and that the causal-
ity of travel is confirmed. All patients included in the 
study were symptomatic, including those with para-
sitic infections such as malaria and schistosomiasis. 
Patients with proven chronic Chagas infection, how-
ever, were included whether or not they were sympto-
matic, owing to the potential life-threatening course 
of the disease. Anonymous, almost real-time, surveil-
lance data that cannot be linked to individual patients 
are entered into the GeoSentinel database. Final diag-
noses are assigned by the treating clinician from an 
internal standardised GeoSentinel list of more than 500 
possible individually coded diagnoses [5]. Patients can 
be assigned as many diagnostic codes as applicable. 
All sites use the best available reference diagnostic 
tests and clinical protocols in their respective coun-
tries. Travellers who presented between 1 January 2010 
and 31 December 2010 to a EuroTravNet site during or 
after travel were included in this analysis and were 
compared with travellers who presented in EuroTravNet 
sites between 1 January and 31 December in 2008 and 
2009. Sites see two distinct groups of patients. The 
first group represents travellers on short trips, includ-
ing mainly tourists, business travellers and non-recent 
migrants or their descendants visiting friends and rela-
tives in their origin countries (VFRs), but also mission-
aries, volunteer workers, aid workers and researchers, 
students travelling for field work, military personnel 
on missions, and individuals travelling to seek medical 
care (medical tourism). The second group represents 
travellers with long-time exposure abroad including 
mainly recent immigrants, usually seen for screening 
when they first enter the migration country, and long-
term exposed expatriates (missionaries, volunteers, 
aid workers and researchers as well as people staying 
abroad for business). 
Data were analysed using SPSS, v16.0 (SPSS Inc, 
Chicago). We calculated proportionate morbidities by 
comparing the number of cases of a specific diagno-
sis (or of a group of specific diagnoses within a syn-
drome group) with all cases of returning ill travellers 
seen during the same time period (or to sub-groups of 
travellers). This allowed us to make comparisons over 
time and between subgroups. Differences in propor-
tions between sub-groups of returning ill travellers 
seen at EuroTravNet sites were tested using Pearson’s 
Chi-square or Fisher’s exact tests. A p value of under 
0.01 was chosen as significant to take into account 
the large number of statistical tests performed. One 
new site had joined EuroTravNet in late 2008, and four 
new sites had joined EuroTravNet in 2010, contribut-
ing together 10% of cases in 2009 and 16% in 2010. 
To allow a reliable comparison by year, cases reported 
by sites that joined after mid-2008 were excluded for 
trend analysis. 
Results
In 2010, data from 7,408 ill travellers were collected. 
There were no significant changes from 2008 to 2010 in 
the number of patients seen at each site (Table 1), nor 
in the age and sex distribution of patients. More non-
VFR short-term travellers were hospitalised in 2009 
Table 1
Number and percentage of travellers seen at the 16 
EuroTravNet sites, 2008–2010 (n=20,757)
Sites 2008 2009 2010
Number  (%) 6,957 (100) 6,392 (100) 7,408 (100)
France (3 sites)
Marseille 351 (5) 496 (8) 395 (5)
Paris 548 (8) 580 (9) 564 (8)
Saint Mandé – – 201 (3)
Germany (2 sites)
Hamburg 1,480 (21) 806 (13) 1,050 (14)
Munich 1,547 (22) 1,441 (23) 1,365  (18)
Italy (1 site)
Brescia 136 (2) 246 (4) 237 (3)
Norway (1 site)
Oslo 498 (7) 476 (7) 588 (8)
Portugal (1 site)
Porto – –  8 (<1)
Sweden (1 site)
Stockholm – – 416 (6)
Switzerland (2 sites)
Geneva 417 (6) 293 (5) 385 (5)
Zurich 225 (3) 132 (2) 245 (3)
Spain (1 site)
Madrid 456 (7) 217 (3) 225 (3)
The Netherland (1 site)
Amsterdam 41 (1) 670 (11) 507 (7)
United Kingdom (3 sites)
Cambridge 126 (2) 125 (2) 152 (2)
Liverpool – – 52 (1)
London 1,132 (16) 910 (14) 1,018 (14)
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and 2010 than in 2008, and fewer patients were known 
to have received a pre-travel consultation (Tables 2 and 
3). The results remained the same when the new sites 
were excluded.
Mortality observed in imported diseases
Five deaths were recorded in 2010. A French tourist 
in their 30s died in Switzerland of melioidosis with 
septic shock, multi-organ failure and acute respira-
tory distress syndrome after a trip to Martinique [6]. 
A migrant from India in their 30s died in Brescia with 
a diagnosis of pyogenic liver abscesses and diabetes 
mellitus. A Swiss in their 50s tourist died of dissemi-
nated Salmonella enterica serovar Weltevreden infec-
tion after returning to Switzerland from Puerto Rico. 
A Norwegian tourist in their 60s died of Legionnaires’ 
disease after a returning from the Czech Republic. A 
Portuguese business traveller in their 50s died with a 
Plasmodium falciparum infection and acute respiratory 
distress syndrome after a four-month stay in Angola. 
This patient had not taken anti-malarial prophylaxis. 
The overall mortality rate was 0.7 per 1,000 ill travel-
lers in 2010, compared with 0.3 per 1,000 in 2009 (two 
deaths due to visceral leishmaniasis, and Acinetobacter 
Table 2
Demographic characteristics of immigrants and expatriates (long-term exposure) seen at the 16 EuroTravNet sites, 2008–
2010 (n=3,494)
Immigrants Expatriates
Year 2008 2009 2010 2008 2009 2010
Number 656 489 639 479 548 683
Sex (%) Female 311 (47) 215 (44) 298 (47) 230 (48) 292 (53) 341 (50)
Age (years) 
Mean 32.6 31.6 32.9 40.2 37 36.8
25th  percentile 26 24 25 30 29 28
Median 32 30 32 40 38 38
75th percentile 39 38 39 53 48 50
Travel reason (%)
Business – – – 123 (26) 105 (19) 150 (22)
Immigration 656 (100) 489 (100) 639 (100) – – –
Medical tourism – – – 0 (0) 0 (0) 0 (0)
Military – – – 0 (0) 0 (0) 0 (0)
M/V/AW/R – – – 348 (73) 442 (81) 533 (78)
Student – – – 0 (0) 1 (0) 0 (0)
Tourism – – – 6 (1) 0 (0) 0 (0)
Risk level (%)
Expatriate – – – 479 (100) 548 (100) 683 (100)
Pre-arranged or organised travel – – – – – –
Risk travela 656 (100) 489 (100) 639 (100) – – –
Clinical setting (%)
Immigration only 656 (100) 489 (100) 639 (100) – – –
Seen after travel – – – 272 (57) 320 (58) 367 (54)
Seen during travel – – – 207 (43) 228 (42) 316 (46)
Inpatient (%) 106 (16) 166 (34) 243 (38) 23 (5) 15 (3) 29 (4)
Pre-travel consultation (%)
Yes 9 (1) 6 (1) 4 (1) 301 (63) 365 (66) 434 (64)
No 60 (9) 130 (27) 144 (23) 54 (11) 41 (8) 76 (11)
Do not know 587 (90) 353 (72) 491 (77) 124 (26) 143 (26) 173 (25)
Live in Europe (%)
Yes 654 (100) 489 (100) 639 (100) 244 (51) 318 (58) 396 (58)
Born in Europe (%)
Yes 28 (4) 26 (5) 62 (10) 423 (88) 474 (87) 568 (83)
AW: aid worker; M: missionary; R: researcher; V: volunteer; VFR: visiting friends and relatives.
a Risk travel: intended to identify travellers who will, by their behaviour, encounter a substantial number of the risks faced by the local 
population. This classification would generally include travelling without pre-booking accommodation for most or all nights, using 
accommodation specific to budget travellers and/or staying in local residents’ homes.
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sp. pneumonia) and with 0.4 per 1,000 in 2008 (three 
deaths due to P. falciparum cerebral malaria, dengue 
shock syndrome and E. coli pyelonephritis) [2,3]. The 
mortality rate associated with malaria was 1.7 per 
1,000 malaria cases in 2010, compared with 0 per 
1,000 in 2009 and 2.7 per 1,000 in 2008. 
Spectrum of imported diseases
Among diagnoses with an identified pathogen (Tables 
4 and 5), malaria and dengue fever accounted for most 
cases of febrile systemic illnesses. Giardia lamblia 
was the most common pathogen identified in acute 
diarrhoea, followed by Campylobacter and Salmonella 
spp. Other common parasitic infections included hook-
worm-related cutaneous larva migrans (CLM), schisto-
somiasis and chronic Chagas disease. 
Febrile systemic illnesses
Malaria
There was an increase in malaria cases reported from 
2008 to 2010 at the EuroTravNet sites, even after the 
Table 3
Demographic characteristics of patients visiting friends and relatives and other short-term travellers seen at the 16 
EuroTravNet sites, 2008–2010 (n=17,263)
VFRs Other short-term travellers
Year 2008 2009 2010 2008 2009 2010
Number 831 800 942 4,991 4,555 5,144
Sex (%) Female 347 (42) 350 (44) 403 (43) 2,510 (50) 2,355 (52) 2,561 (50)
Age (years) 
Mean 33.3 34.7 36.7 38.5 37.9 38.7
25th  percentile 23 25 28 28 27 27
Median 34 35 37 36 35 36
75th percentile 45 45 46 49 48 49
Travel reason (%)
Business – – – 606 (12) 600 (13) 741 (14)
Immigration – – – – – –
Medical tourism – – – 10 (0) 24 (1) 27 (1)
Military – – – 40 (1) 61 (1) 73 (1)
M/V/AW/R – – – 1,221 (25) 838 (18) 996 (19)
Student – – – 91 (2) 157 (3) 131 (3)
Tourism – – – 3,023 (61) 2,875 (63) 3,176 (62)
VFRs 831 (100) 800 (100) 942 (100) – – –
Risk level (%)
Expatriate – – – – – –
Pre-arranged or organised travel – – – 1,570 (32) 1,698 (37) 2,015 (39)
Risk travela 831 (100) 800 (100) 942 (100) 3,367 (68) 2,780 (61) 3,074 (60)
Missing information – – – 54 (1) 77 (2) 55 (1)
Clinical setting (%)
Immigration only – – – – – –
Seen after travel 819 (99) 779 (97) 934 (99) 4,616 (93) 4,296 (94) 4,895 (95)
Seen during travel 12 (1) 21 (3) 8 (1) 375 (8) 259 (6) 249 (5)
Inpatient (%) 261 (31) 290 (36) 390 (41) 379 (8) 461 (10) 682 (13)
Pre-travel consultation (%)
Yes 203 (24) 212 (27) 221 (24) 2,647 (53) 2,182 (48) 2,321 (45)
No 329 (40) 381 (48) 472 (50) 1,111 (22) 1,116 (25) 1,524 (30)
Do not know 299 (36) 207 (26) 249 (26) 1,233 (25) 1,257 (28) 1,299 (25)
Live in Europe (%)
Yes 817 (98) 782 (98) 934 (99) 4,640 (93) 4,324 (95) 4,933 (96)
Born in Europe (%)
Yes 260 (31) 239 (30) 264 (28) 4,570 (92) 4,214 (93) 4,757 (93)
AW: aid worker; M: missionary; R: researcher; V: volunteer; VFR: visiting friends and relatives.
a Risk travel: intended to identify travellers who will, by their behaviour, encounter a substantial number of the risks faced by the local 
population. This classification would generally include travelling without pre-booking accommodation for most or all nights, using 
accommodation specific to budget travellers and/or staying in local residents’ homes.
Diagnosis
Num
ber (proportional m
orbidity)
 
Im
m
igrants (n=2,416)
Expatriates (n=2,369)
2008
excluding 
new
 sites
a
n=
656
2009
excluding 
new
 sites
a
n=489
2010
excluding 
new
 sites
a
n=
632
2010 
all sites
n=
639
P value
2008
excluding 
new
 sites
a
n=479
2009
excluding 
new
 sites
a
n=
548
2010
excluding 
new
 sites
a
n=
659
2010
all sites 
n=
683
P value
Plasm
odium
 falciparum
 m
alaria 
13 (2)
6 (1)
20 (3)
21 (3)
0.080
12 (3)
10 (2)
11 (2)
14 (2)
0.581
P. vivax m
alaria
2 (0)
9 (2)
3 (1)
3 (1)
0.008
3 (1)
0 (0)
0 (0)
0 (0)
0.023
Severe m
alaria
b
0 (0)
2 (<1)
2 (<1)
2 (<1)
0.294
3 (1)
1 (<1)
0 (0)
1 (<1)
0.095
Non-falciparum
 m
alaria (includes P. vivax)
3 (1)
10 (2)
6 (1)
6 (1)
0.033
6 (1)
3 (1)
3 (1)
3 (<1)
0.246
Dengue fever
0 (0)
0 (0)
2 (<1)
2 (<1)
0.163
7 (2)
6 (1)
10 (2)
10 (2)
0.801
Chikungunya
0 (0)
1 (<1)
0 (0)
0 (0)
0.268
2 (<1)
0 (0)
1 (<1)
1 (<1)
0.279
Giardia
6 (1)
5 (1)
4 (1)
4 (1)
0.755
8 (2)
7 (1)
9 (1)
10 (2)
0.858
Cam
pylobacter
0 (0)
0 (0)
0 (0)
0 (0)
-
2 (<1)
1 (<1)
2 (<1)
3 (<1)
0.787
Salm
onella
c
1 (<1)
0 (0)
4 (1)
4 (1)
0.103
6 (1)
0 (0)
3 (<1)
3 (<1)
0.022
Active tuberculosis (all cases)
60 (9)
90 (18)
155 (25)
156 (24)
<0.001
2 (<1)
2 (<1)
0 (0)
0 (0)
0.272
Pulm
onary tuberculosis
26 (4)
51 (10)
93 (15)
94 (15)
<0.001
0 (0)
0 (0)
0 (0)
0 (0)
-
Schistosom
iasis
11 (2)
18 (4)
23 (4)
24 (4)
0.057
14 (3)
17 (3)
28 (4)
29 (4)
0.402
Chronic Chagas disease
93 (14)
30 (6)
58 (9)
58 (9)
<0.001
0 (0)
0 (0)
0 (0)
0 (0)
-
Cutaneous larva m
igrans
0 (0)
0 (0)
2 (<1)
2 (<1)
0.163
2 (<1)
1 (<1)
0 (0)
0 (0)
0.256
n: total num
ber of ill patients (all diagnoses including those not due to an infectious cause)
a  Cases reported by sites that joined EuroTravNet after m
id-2008 w
ere excluded to allow
 a reliable com
parison by year.
b  Severe m
alaria w
as defined according to W
orld Health O
rganization criteria [7].
c  Salm
onella Typhi and other species and S. Paratyphi.
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Table 4
N
um
ber of cases and proportional m
orbidity for selected diagnoses w
ith identified pathogens in people w
ith long-term
 exposure seen at EuroTravN
et sites, 2008–2010 (n=4,785) 
Diagnosis
Num
ber (proportional m
orbidity)
 
Im
m
igrants (n=2,416)
Expatriates (n=2,369)
2008
excluding 
new
 sites
a
n=
656
2009
excluding 
new
 sites
a
n=489
2010
excluding 
new
 sites
a
n=
632
2010 
all sites
n=
639
P value
2008
excluding 
new
 sites
a
n=479
2009
excluding 
new
 sites
a
n=
548
2010
excluding 
new
 sites
a
n=
659
2010
all sites 
n=
683
P value
Plasm
odium
 falciparum
 m
alaria 
13 (2)
6 (1)
20 (3)
21 (3)
0.080
12 (3)
10 (2)
11 (2)
14 (2)
0.581
P. vivax m
alaria
2 (0)
9 (2)
3 (1)
3 (1)
0.008
3 (1)
0 (0)
0 (0)
0 (0)
0.023
Severe m
alaria
b
0 (0)
2 (<1)
2 (<1)
2 (<1)
0.294
3 (1)
1 (<1)
0 (0)
1 (<1)
0.095
Non-falciparum
 m
alaria (includes P. vivax)
3 (1)
10 (2)
6 (1)
6 (1)
0.033
6 (1)
3 (1)
3 (1)
3 (<1)
0.246
Dengue fever
0 (0)
0 (0)
2 (<1)
2 (<1)
0.163
7 (2)
6 (1)
10 (2)
10 (2)
0.801
Chikungunya
0 (0)
1 (<1)
0 (0)
0 (0)
0.268
2 (<1)
0 (0)
1 (<1)
1 (<1)
0.279
Giardia
6 (1)
5 (1)
4 (1)
4 (1)
0.755
8 (2)
7 (1)
9 (1)
10 (2)
0.858
Cam
pylobacter
0 (0)
0 (0)
0 (0)
0 (0)
-
2 (<1)
1 (<1)
2 (<1)
3 (<1)
0.787
Salm
onella
c
1 (<1)
0 (0)
4 (1)
4 (1)
0.103
6 (1)
0 (0)
3 (<1)
3 (<1)
0.022
Active tuberculosis (all cases)
60 (9)
90 (18)
155 (25)
156 (24)
<0.001
2 (<1)
2 (<1)
0 (0)
0 (0)
0.272
Pulm
onary tuberculosis
26 (4)
51 (10)
93 (15)
94 (15)
<0.001
0 (0)
0 (0)
0 (0)
0 (0)
-
Schistosom
iasis
11 (2)
18 (4)
23 (4)
24 (4)
0.057
14 (3)
17 (3)
28 (4)
29 (4)
0.402
Chronic Chagas disease
93 (14)
30 (6)
58 (9)
58 (9)
<0.001
0 (0)
0 (0)
0 (0)
0 (0)
-
Cutaneous larva m
igrans
0 (0)
0 (0)
2 (<1)
2 (<1)
0.163
2 (<1)
1 (<1)
0 (0)
0 (0)
0.256
n: total num
ber of ill patients (all diagnoses including those not due to an infectious cause)
a  Cases reported by sites that joined EuroTravNet after m
id-2008 w
ere excluded to allow
 a reliable com
parison by year.
b  Severe m
alaria w
as defined according to W
orld Health O
rganization criteria [7].
c  Salm
onella Typhi and other species and S. Paratyphi.
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Table 5
N
um
ber of cases and proportional m
orbidity for selected diagnoses w
ith identified pathogens in people w
ith short-term
 exposure seen at EuroTravN
et sites, 2008–2010 (n=22,703) 
Diagnosis
Num
ber (proportional m
orbidity)
 
People visiting friends and relatives (n=3,419)
O
ther short-term
 travellers (n=
19,284)
2008
Excluding 
new
 sites
a
n=
831
2009
excluding 
new
 sites
a
n=
800
2010
excluding 
new
 sites
a
n=
846
2010 
all sites
n=
942
P value
2008
Excluding 
new
 sites
a
n=4,991
2009
excluding 
new
 sites
a
n=4,555
2010
excluding 
new
 sites
a
n=4,594
2010 
all sites
n=
5,144
P value
P. falciparum
 m
alaria 
169 (20)
192 (24)
243 (29)
277 (29)
<0.001
73 (2)
88 (2)
119 (3)
136 (3)
<0.001
P. vivax m
alaria
9 (1)
3 (<1)
20 (2)
21 (2)
0.001
17 (<1)
27 (1)
30 (1)
55 (1)
0.078
Severe m
alaria
b
1 (<1)
6 (1)
14 (2)
15 (2)
0.003
8 (<1)
4 (<1)
15 (<1)
17 (<1)
0.027
N
on-falciparum
 m
alaria (includes P. vivax)
36 (4)
25 (3)
42 (5)
43 (5)
0.166
59 (1)
43 (1)
65 (1)
94 (2)
0.114
Dengue fever
16 (2)
22 (3)
25 (3)
27 (3)
0.368
108 (2)
144 (3)
290 (6)
319 (6)
<0.001
Chikungunya
2 (<1)
0 (0)
4 (1)
4 (<1)
0.149
8 (<1)
17 (<1)
23 (1)
25 (1)
0.015
Giardia
10 (1)
8 (1)
10 (1)
11 (1)
0.913
169 (3)
165 (4)
172 (4)
190 (4)
0.630
Cam
pylobacter
3 (<1)
14 (2)
8 (1)
11 (1)
0.019
82 (2)
82 (2)
118 (3)
160 (3)
0.003
Salm
onella
c
13 (2)
17 (2)
24 (3)
27 (3)
0.202
59 (1)
55 (1)
72 (2)
93 (2)
0.189
Active tuberculosis (all cases)
28 (3)
39 (5)
24 (3)
26 (3)
0.076
12 (<1)
6 (<1)
15 (<1)
17 (<1)
0.154
Pulm
onary tuberculosis
11 (1)
24 (3)
16 (2)
17 (2)
0.053
2 (<1)
3 (<1)
8 (<1)
10 (<1)
0.075
Schistosom
iasis
18 (2)
23 (3)
23 (3)
24 (3)
0.635
85 (2)
76 (2)
70 (2)
75 (2)
0.767
Chronic Chagas disease
1 (<1)
0 (0)
2 (<1)
2 (<1)
0.387
0 (0)
0 (0)
0 (0)
0 (0)
-
Cutaneous larva m
igrans
2 (<1)
4 (1)
4 (1)
4 (<1)
0.659
93 (2)
103 (2)
96 (2)
106 (20)
0.390
n: total num
ber of ill patients (all diagnoses including those not due to an infectious cause)
a  Cases reported by sites that joined EuroTravNet after m
id-2008 w
ere excluded to allow
 a reliable com
parison by year.
b  Severe m
alaria w
as defined according to W
orld Health O
rganization criteria [7].
c  Salm
onella Typhi and other species and S. Paratyphi.
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exclusion of sites that joined EuroTravNet after mid-
2008 (Figure 1). The proportionate morbidity from 
malaria was dramatically higher in VFRs than in other 
groups. A significant increase over time in numbers 
and proportionate morbidity was observed in both the 
group of VFRs and other traveller groups (Figure 2). The 
increase was observed in patients returning from all 
main countries of exposure for malaria with the excep-
tion of Burkina Faso where no variation was seen over-
time (Figure 1). There was a significant increase in the 
proportion of patients with malaria seen at the sites in 
Paris (France) and Brescia (Italy), which together con-
tributed more than half of the cases (57% in 2010), as 
well as in those seen in Munich and Hamburg (Germany) 
and Madrid (Spain) (Figure 2). 
Plasmodium falciparum malaria was the most com-
monly reported species with 426 cases in 2010. P. 
falciparum malaria proportionate morbidity (number 
of P. falciparum malaria cases per 100 ill travellers) 
increased from 4% in 2008 to 6% in 2010 (p<0.001), pri-
marily in patients returning from sub-Saharan Africa. 
Most cases were in VFRs and other short-term travel-
lers. There were 35 patients with severe P. falciparum 
malaria (one death) in 2010 compared with 13 in 2009 
(no deaths) and 12 in 2008 (one death) (p=0.003). In 
2010, the mean age of patients with severe malaria 
was 40.6 years (range 3–73 years), four patients were 
children. Eight of those patients were tourists, eight 
were business travellers, volunteers, research or aid 
workers, while the remaining 19 were immigrants or 
VFRs (54%). 
Plasmodium vivax malaria proportionate morbidity 
(number of P. vivax malaria cases per 100 ill travellers) 
increased from 0.5% in 2008 to 1% in 2010 (p=0.027). 
Most cases were VFRs and other short-term travellers 
returning from India.
Dengue virus infection
Dengue virus was the second most frequent cause of 
fever among ill returning travellers, with 357 patients 
in 2010. There was a statistically significant increase 
in proportional morbidity, from 2% in 2008 to 5% in 
2010 (p<0.001). Most cases were in non-VFR short-term 
travellers. The 2009–10 increase was primarily due to 
a peak of cases between May and October 2010 (Figure 
3). In 2010, patients returning from south-east Asia 
accounted for 40% of dengue patients, those from the 
Caribbean for 24% and those from South America for 
12%. The seasonal pattern could be partly explained 
by preferential destinations of different traveller 
groups. Consequently, in September 2010, there were 
more patients, predominantly Germans, with expo-
sure in south-east Asia, mainly Thailand. From June to 
September 2010, there were more French patients with 
exposure in Guadeloupe and Martinique. The increase 
in October 2010 was spread over different EuroTravNet 
sites and exposure countries, but German patients 
returning from Indonesia were overrepresented. Cases 
were also seen in 2010 in travellers returning from 
Figure 1
Number of all malaria cases per year reported by 
EuroTravNet sites, 2008-2010 (n=1,245)
Cases reported by sites that joined EuroTravNet after mid-2008 
were excluded to allow a reliable comparison by year.
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Brazil, Surinam and India. Unexpected places of expo-
sure, such as the Comoros Islands, Zanzibar and Benin 
were also recorded. There was one case of haemor-
rhagic dengue fever in a 53 year-old French male VFR 
from Martinique.
Chikungunya virus infections
The proportionate morbidity for diagnosed chikun-
gunya virus infections was 0.2% in 2008 and 0.4% 
on 2010. Most patients had exposure in India and 
Indonesia and occurred in early 2010. 
Gastro-intestinal diseases
A total of 215 G. lamblia infections were recorded in 
2010. While G. lamblia and Salmonella spp. proportion-
ate morbidity remained constant over time, the pro-
portionate morbidity of Campylobacter spp. infections 
increased from 1.3% in 2008 to 2.0% in 2010 (p=0.002), 
mainly in patients returning from India, Thailand and 
Pakistan. G. lamblia was identified in 16% of patients 
with acute diarrhoea. The proportion of patients with 
acute diarrhoea due to Campylobacter increased from 
7% in 2008 to 12 % in 2010 (p=0.001). 
Respiratory and other diseases 
Tuberculosis
The proportionate morbidity of active tuberculosis 
increased from 1.5% in 2008 to 3.1% in 2010 (p<0.001). 
A total of 121 patients with pulmonary tuberculosis 
were recorded in 2010, a threefold increase in the pro-
portionate morbidity of pulmonary tuberculosis from 
2008 to 2010 (p<0.001). Most cases were reported in 
immigrants and VFRs, originating mainly from India, 
Pakistan and Romania. 
Figure 2
Proportion of malaria cases among all ill immigrants, 
people visiting friends and relatives, and other travellers 
returning to EuroTravNet sites, 2008–2010 (n=1,245 
malaria cases)
VFR: visiting friends and relatives.
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Figure 3
Number of dengue fever cases seen at EuroTravNet sites, 
per month, 2008–2010 (n=630)
Cases reported by sites that joined EuroTravNet after mid-2008 
were excluded to allow a reliable comparison by year.
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C. Travellers returning from the Caribbean (n=108)
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Other parasitic infections 
In 2010, 152 Schistosoma infections were recorded 
and most cases were diagnosed in patients returning 
from Africa. Egypt, Ghana, Malawi, Mali and Uganda 
accounted for 41% of infections. Six patients may have 
acquired schistosomiasis in south-east Asia and two 
in Brazil. Most Schistosoma infections (40%) occurred 
in missionaries, volunteers and aid workers, followed 
by tourists (19%), VFRs (16%) and immigrants (13%). In 
2010, 112 CLM infections were recorded and most cases 
were acquired in Thailand, Brazil and Malaysia (46%) 
and mostly reported from tourists (80%) followed by 
business travellers (6%). In 2010, 60 cases of Chagas 
disease were recorded. All but two patients diagnosed 
with Chagas disease were immigrants from Bolivia; 
the other two were from Paraguay and Ecuador. Two 
thirds of the patients (67%) had symptoms that could 
be attributed to Chagas disease, and 21% of those had 
confirmed visceral involvement and 79% were in the 
indeterminate phase. The proportionate morbidities 
of schistosomiasis, CLM and Chagas disease did not 
increase significantly from 2008 to 2010. 
Discussion
Between 2008 and 2010, 10 deaths were reported 
among travellers seen within our network. This may 
significantly underestimate the travel-related mortal-
ity in Europe, as it does not include patients who died 
overseas or patients not seen in our centres. In other 
series published in the last decade on patients with 
imported infections presenting with fever, malaria was 
found to be the most important cause of travel-related 
mortality [8]. Case fatality rates of imported malaria 
do not fluctuate much and have been about 0.5 to 1% 
of reported cases in the past 20 years [9,10] compared 
with less than 0.4% in our experience. 
We observed distinct patterns of morbidity related to 
the duration of stay in tropical areas. Malaria, den-
gue and chikungunya virus infections, diarrhoea and 
CLM were mostly seen in short-term travellers, while 
tuberculosis, Chagas disease and Schistosoma infec-
tions were mostly seen in long-term travellers. Reason 
for travel was also associated with some infections, 
including malaria in VFRs, CLM in tourists, or tubercu-
losis and Chagas disease in immigrants.
Malaria remains the most common cause of fever among 
travellers to tropical countries receiving a diagnosis in 
the EuroTravNet/Geosentinel database. The significant 
increase in malaria cases reported to EuroTravNet in 
2010 confirms the trend already observed in 2009 [3] 
and was not biased by the addition of new sites to the 
network in 2010 nor by an overall increase of patients 
seen at each EuroTravNet clinic. It may reflect a chang-
ing trend in imported malaria in Europe, possibly due 
to changes in destinations. However, the increase was 
statistically significant in only five EuroTravNet sites. 
Despite a global trend in declining malaria case num-
bers in endemic areas over the past decade, World 
Health Organization (WHO) statistics on imported 
malaria cases in Europe show a contradictory trend 
with increased case numbers in the past two years 
[11] which calls for intensified EuroTravNet surveillance 
of malaria in travellers and migrants. According to 
data from the WHO, the overall incidence of imported 
malaria in the European Union had decreased gradually 
from 2.9 cases per 100,000 population in 2000 to 1.64 
per 100,000 in 2008, but there was a slight increase to 
1.67 per 100,000 in 2009 [11,12]. This correlates with 
our own results, with national malaria surveillance 
data in France that estimated 3,990 imported cases in 
2009 and 4,600 in 2010 [13], and also with data from 
the United Kingdom, where 1,370 imported cases were 
recorded in 2008, 1,495 in 2009 and 1,761 in 2010 [14]. 
Odolini et al, [3] emphasised the public health conse-
quences of increasing importation of P. vivax malaria 
to Mediterranean Europe that could lead to the reap-
pearance of autochthonous malaria. Sporadic cases 
of autochthonous P. vivax malaria have already been 
observed in southern France [15] and Spain [16] and 
more recently in Greece [17,18]. Given the high propor-
tion of immigrants and VFRs among malaria patients, 
specific health education programmes should be 
launched in these populations who are known to seek 
pre-travel advice less frequently compared with other 
travellers [17], which is confirmed in our survey (see 
Tables 2 and 3). This is important because patients 
with P.vivax malaria could act as reservoirs for autoch-
thonous transmission in Europe.
We highlight that dengue virus is an increasingly fre-
quent cause of fever in travellers returning from the 
tropics, which corroborates results from single-cen-
tre surveys recently conducted in Germany, Denmark 
and the Netherlands [18-22]. The increased incidence 
of dengue fever in travellers returning from south-
east Asia and from the Caribbean may be the conse-
quence of outbreaks that occurred in these areas in 
2010 [24,24]. Surveillance of sentinel travellers allows 
us to identify dengue virus circulation in areas where 
it was unknown or rarely described, notably in Benin 
and the Comoros Islands [25,26]. Whether this reflects 
extremely rare transmission from sylvatic animals 
to humans or transmission between humans, is not 
clear. A number of patients with dengue and chikun-
gunya virus infections in our survey were recorded in 
southern France and Italy where autochthonous trans-
mission has recently been observed [27-29]. Overall, 
16% of patients with chikungunya fever were seen in 
Marseille, where Aedes albopictus has recently been 
detected [30]. This emphasises the need for increased 
attention to surveillance of dengue and chikungunya 
fever in travellers returning to areas where A. albopic-
tus is present.
The high proportion of G. lamblia infections among 
European travellers suffering from diarrhoea is note-
worthy. Travellers should receive stool examinations 
especially in the context of chronic gastrointestinal com-
plaints accompanied by intermittent diarrhoea. Data 
on imported resistant bacteria are not systematically 
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reported to the EuroTravNet database. However, 
most cases of diarrhoea due to Campylobacter and 
Salmonella spp. followed exposure in Asian countries 
where fluoroquinolone resistance is common [31,32]. 
This suggests that fluoroquinolones should no longer 
be prescribed as first-line empiric treatment for travel-
lers’ diarrhoea. A macrolide such as azithromycin may 
be a better choice [31]. 
Our survey confirms that tuberculosis is an issue in 
immigrants coming to Europe from high-incidence 
countries. In the author’s view, health systems should 
facilitate early access and treatment of patients with 
tuberculosis (regardless of their legal status) to prevent 
further spread of the disease. In addition, substantial 
numbers of chronic Chagas disease were reported 
to EuroTravNet in 2010, mainly at the site in Madrid 
among immigrants from Bolivia. This is comparable to 
the data from 2008–09 [33]. 
Schistosomiasis and CLM continue to cause a sig-
nificant proportion of imported parasitic diseases in 
European travellers. Schistosomiasis is easily pre-
vented by avoiding swimming in open water, and this 
recommendation should be re-enforced when giv-
ing pre-travel advice. CLM is more difficult to prevent 
because most tourist travellers acquire this disease 
during typical holiday leisure activities on the beaches 
and prevention is mainly by public health measures 
that keep dogs and cats off the beach. 
The major strength of our analysis is the multi-centre 
nature of EuroTravNet, which provided a large number of 
patients from many countries and captured many types 
of travellers, and its focus on proportionate morbidity. 
The limitations of this method of analysis have been 
discussed [1,5]. In particular, because the denomina-
tor data (number of travellers) cannot be ascertained, 
it is not possible to calculate incidence rates or abso-
lute risk. Also, the data may not be representative of 
the overall population of travellers, and do not include 
the broad spectrum of illnesses typically seen at non-
specialised primary care practices where people with 
mild or self-limited conditions present with higher fre-
quency. Due to the nature of GeoSentinel/EuroTravNet 
clinics, illnesses acquired after travel to non-tropical 
destinations or non-infectious travel-related illnesses 
may be under-represented. However, the GeoSentinel 
database has been identified as a valuable source of 
data on the epidemiology of travel-related illnesses 
[34]. Surveillance over this three-year period also iden-
tified an increase in imported vector-borne diseases at 
European sentinel sites with significantly raised num-
bers of malaria and dengue fever. This has important 
public health implications and warrants close surveil-
lance in view of the presence in Europe of Anopheles 
(competent for P. vivax transmission) and Aedes vec-
tors (competent for dengue and chikungunya virus 
transmission), allowing real-time intervention to pre-
vent subsequent autochthonous transmission. 
Finally, it is of concern that there were more hospi-
talised patients and fewer patients who were known 
to have had a pre-travel consultation, compared with 
2008–09. This should alert public health authorities to 
the need to reinforce preventive activities among inter-
national travellers.
In summary, we have investigated travel-associated 
morbidity in European travellers in 2010 and showed 
that illness patterns in sentinel travellers, captured 
through the activities of the EuroTravnet/Geosentinel 
Network, continue to highlight the potential role of 
travellers in the emergence of infectious diseases of 
public health concern in Europe. 
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